{"id":"placebon","rwe":[],"tags":[],"safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"}]},"trials":[],"_chembl":null,"aliases":["Normal saline"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the serotonin receptor, which leads to a decrease in serotonin levels in the brain, resulting in a reduction of anxiety symptoms.","oneSentence":"Placebon is a small molecule that targets the serotonin receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:04.199Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"indications":{"approved":[{"name":"Generalized anxiety disorder"}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05902598","phase":"PHASE3","title":"A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome","status":"COMPLETED","sponsor":"Visirna Therapeutics HK Limited","startDate":"2023-07-10","conditions":"Familial Chylomicronemia Syndrome","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":15,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_3","status":"active","brandName":"Placebon","genericName":"Placebon","companyName":"Visirna Therapeutics HK Limited","companyId":"visirna-therapeutics-hk-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebon is a small molecule that targets the serotonin receptor. Used for Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}